PatientsVille.com Logo

Keratitis and Dexagel

PatientsVille

Keratitis Symptoms and Causes

Your cornea is the outermost layer of your eye. It is clear and shaped like a dome. The cornea helps to shield the rest of the eye from germs, dust, and other harmful matter. It also helps your eye to focus. If you wear contact lenses, they float on top of your corneas.

Problems with the cornea include

  • Refractive errors
  • Allergies
  • Infections
  • Injuries
  • Dystrophies - conditions in which parts of the cornea lose clarity due to a buildup of cloudy material

Treatments of corneal disorders include medicines, corneal transplantation, and corneal laser surgery.

NIH: National Eye Institute

Check out the latest treatments for keratitis

keratitis treatment research studies

Dexagel clinical trials, surveys and public health registries


Find Drug Side Effect reports



Dexagel Side Effects

Corneal Deposits (3)
Impaired Healing (2)
Corneal Erosion (2)
Corneal Perforation (1)
Corneal Neovascularisation (1)
Visual Acuity Reduced (1)
Corneal Transplant (1)
Corneal Infiltrates (1)
Eyelid Ptosis (1)
Transplant (1)
Lacrimal Disorder (1)
Intraocular Pressure Increased (1)
Disease Recurrence (1)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Keratitis Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Matrix Therapy And Bacterial Keratitis
Condition: Bacterial Keratitis
Interventions: Device: RGTA OTR4120 (CACICOL20);   Device: physiological salt solution
Outcome Measures: Epithelial corneal surface healing;   Healing time of total corneal epithelial wound;   Visual acuity;   Ulcer deep;   Healing Keratitis rate
2 Recruiting Ultraviolet-A and Riboflavin Treatment for Infectious Keratitis
Condition: Infectious Keratitis
Intervention: Other: Ultraviolet-A and riboflavin
Outcome Measure: Resolution of Signs and Symptoms of Infectious Keratitis
3 Recruiting Collagen Cross-linking in Infectious Keratitis Trial
Conditions: Infectious Keratitis;   Bacterial Keratitis;   Fungal Keratitis
Intervention: Procedure: Collagen cross-linking
Outcome Measures: decrement of infiltration size;   number of participants with adverse events
4 Recruiting Evaluation of Safety and Efficacy of rhNGF in Patients With Stage 2 and 3 Neurotrophic Keratitis.
Conditions: Neurotrophic Keratitis;   Keratitis;   Corneal Ulcer
Interventions: Drug: rhNGF 10 µg/ml eye drops solution;   Drug: rhNGF 20 µg/ml eye drops solution;   Drug: Placebo
Outcome Measures: Complete healing of the persistent epithelial defect or corneal ulcer;   Percentage of patients experiencing complete healing of the persistent epithelial defect or corneal;   Presence of Anti-NGF antibodies;   Change in ocular tolerability
5 Recruiting Pseudomonal Type Three Secretion System and Contact Lens Associated Microbial Keratitis
Condition: Keratitis; Infectious Disease (Manifestation)
Intervention:
Outcome Measures: bacterial adhesion assay;   Identification of bacterial colonization to worn contact lenses
6 Recruiting The Asia Cornea Society Infectious Keratitis Study
Condition: Corneal Ulcer
Intervention:
Outcome Measures: Resolution of infectious Keratitis;   Number of acute surgical interventions required.;   Visual acuity outcome of management.
7 Recruiting The Flocked Swab and the Traditional Fiber Swab for the Diagnosis of the Herpes Simplex Epithelial Keratitis
Condition: Herpes Simplex Keratitis
Intervention: Procedure: Corneal sampling
Outcome Measures: Result of the culture;   Time before positivity of the culture;   Viral load concentration
8 Not yet recruiting Safety and Efficacity of Corneal Collagen Crosslinking in Infectious Keratitis (Bacterial and Fungal ): Randomized,Controlled, Prospective Study. (CXL)
Conditions: Bacterial Keratitis;   Fungal Keratitis
Interventions: Device: Crosslinking;   Drug: antibiotic treatment
Outcome Measures: Duration of corneal complete epithelial healing in days.;   Size of the corneal scar;   Corneal thinning;   Gain of visual acuity
9 Recruiting Efficacy and Safety Assessment of T4020 Versus Vehicule in Patients With Chronic Neurotrophic Keratitis or Corneal Ulcer
Conditions: Keratitis;   Corneal Ulcer
Intervention: Device: T4020
Outcome Measures: evaluation of the Keratitis/ulcer area;   Number of adverse events recorded;   Best corrected visual acuity
10 Not yet recruiting Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Conditions: Ocular Inflammation;   Infection Associated Blepharitis;   Keratitis;   Conjunctivitis, Bacterial
Interventions: Drug: azithromycin 1.5%/Loteprednol 0,5% + placebo;   Drug: azithromycin 1.5% + Loteprednol 0,5% (separately)
Outcome Measures: Clinical cure;   irradication of pathogens
11 Recruiting Double-Masked Trial of NOVA22007 (1mg/mL Ciclosporin/Cyclosporine) Versus Vehicle in Pediatric Patients With Active Severe Vernal Keratoconjunctivitis
Condition: Vernal Keratoconjunctivitis
Interventions: Drug: NOVA22007 ''Ciclosporin'';   Drug: Placebo
Outcome Measures: Compare the composite efficacy score over 4 months of treatment base on Keratitis and need for rescue medication for two different dosing regimens of NOVA22007 versus placebo (vehicle of the formulation).;   Tolerability of will be assessed monthly through slit lamp examination, BCDVA, IOP and safety through vital signs, AE reporting, CsA blood levels and biological tests.;   The main secondary endpoints are the assessment of the corneal Keratitis, the use of rescue therapy and the occurrence of ulcer which will be assessed monthly.
12 Recruiting Mucin Balls and Corneal Inflammation Events
Condition: Corneal Inflammation
Interventions: Device: lotrafilcon A;   Device: comfilcon A;   Device: balafilcon A
Outcome Measures: Corneal Inflammatory Events;   Corneal Inflammatory Events Post 4 Months Randomization to 8 Months
13 Unknown  Reliability of Pachymetry Measurement With FD-oCT, ORA, Confoscan 4 and Ultrasound
Condition: Keratitis
Intervention:
Outcome Measures: Repeatability and reproducibility of corneal thickness measurement;   Comparing central corneal thickness measurement among FD-OCT, ORA, and USP
14 Not yet recruiting Robotic Surgery of the Ocular Surface
Conditions: Keratitis;   Pterygium;   Corneal Opacity Corneal Thinning;   Corneal Perforation
Interventions: Device: 1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique);   Device: Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique);   Device: Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot
Outcome Measure: Respect for different phases of the operating procedure of each intervention.
15 Unknown  Antibiotic Susceptibility of Conjunctival Bacterial Isolates From Refractive Surgery Patients
Condition: Bacterial Keratitis
Intervention:
Outcome Measure: Minimum inhibitory concentrations of commonly used antibiotics are determined using an E-test.
16 Recruiting Mycotic Ulcer Treatment Trial II
Conditions: Corneal Ulcer;   Eye Infections, Fungal
Interventions: Drug: Voriconazole;   Drug: Placebo
Outcome Measures: Rate of perforation;   Best spectacle-corrected logMAR visual acuity;   Best spectacle-corrected logMAR visual acuity only in Indian sites;   Hard contact-lens corrected visual acuity measured in logMAR;   Size of infiltrate/scar;   Time to resolution of epithelial defect;   Number of adverse events;   Minimum inhibitory concentration of isolates;   Microbiological cure at 7 days
17 Not yet recruiting Changes in Tear Osmolarity Over Time With Sustained Use of TheraTears
Condition: Dry Eye Syndrome
Intervention: Other: TheraTears lubricating drops
Outcome Measures: Change in tear osmolarity;   Change in the Ocular Surface Disease Index (OSDI) score;   Change in visual acuity;   Change in Tear Break Up Time;   Change in Phenol Red Thread test;   Change in corneal and conjunctival staining
18 Unknown  Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision
Condition: Primary Pterygium
Intervention: Drug: Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%
Outcome Measures: rate of corneal epithelial defect closure;   toxicity findings: punctate Keratitis, inferior conjunctival hyperemia, conjunctival papillary reaction
19 Recruiting Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases
Condition: Eye Diseases
Intervention:
Outcome Measure:
20 Recruiting Effect of Topical Glaucoma Therapy on Tear Film Stability in Healthy Subjects
Condition: Healthy
Interventions: Drug: Timoptic® 0.5%;   Drug: Timophtal sine® 0.5%;   Device: Genteal HA®;   Device: Hylo-Comod®;   Device: Thealoz®
Outcome Measures: Tear film thickness;   Break up time (BUT)